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Abstract
Aims: This study explored family physicians’ (FPs) stated practices and decision-making
for lung cancer screening.
Methods: Cross-sectional survey of a stratified random sample of Saskatchewan FPs
using single item questions and simulated clinical scenarios.
Findings: Wide variations in FPs’ lung cancer screening practices exist in their decision
to screen and choice of screening test. Certain physician, patient and non-medical factors
influence FPs’ decision-making contrary to their perception of guidelines.
Conclusions: The high self-reported prevalence and measured inclination to screen in
clinical scenarios contrary to prevailing guidelines adds unnecessary health care costs and
has potential to cause harm.
Significance: First and unique study regarding lung cancer screening in family practice
in Canada. It contributes to the literature about existing FP practices and decision-making
regarding lung cancer screening and highlights implications to health care cost, patient
care and CME initiatives.

Keywords: Lung Cancer Screening, Decision-making, Clinical Practice Guidelines,
Family Medicine.
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Chapter 1
Introduction
1.1 Chapter Overview
This chapter describes the significance of lung cancer, guidelines, decision-making and
practice variations in behaviour of family physicians (FPs) regarding lung cancer
screening. The literature reports variation in medical practice that is not based on
carefully constructed guidelines. This variation is seen in procedures where evidence is
unclear or conflicting as well as where there is a clear consensus in guidelines.1 Factors
such as anxiety about cancer and expectation expressed by patients for a screening test
influence FPs to order screening tests.2
The decision-making context in which screening decisions are made is explored. Issues
about screening and guidelines are highlighted; physician’s attitude towards screening in
general, cancer screening, lung cancer screening, use of guidelines and variation in their
practice behaviour are presented.
The variation in guidelines, risk of lung cancer and limited detection and treatment
options raise questions about FPs decision-making on lung cancer screening for their
patients. For example, do they screen for lung cancer? If they do, how often do they
screen and which screening tests are ordered? Additionally the literature lacks evidence
on how those decisions are made. Specifically, what factors influence a FP to order or not
order a screening test for lung cancer? Do patient’s preferences, fears and expectations,
physician factors and the influence of colleagues, personal experience with cancer and
availability, access and cost of the screening test influence their decision making for lung
cancer screening?
This chapter concludes with a summary, which synthesizes the rationale for research
based on gaps in knowledge and evidence presented in the literature review. Finally, the
study research questions are formulated, corresponding research objectives defined and a
conceptual FP lung cancer screening decision making model introduced.
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1.2 Literature Review
1.2.1 Significance of Lung Cancer
Lung cancer accounts for the highest cancer mortality rate for both men and women
according to American Cancer Society data.3 The 2011 statistics show it is the leading
cause of cancer death for men aged 40 and older, and for women aged 60 and older.3 The
five-year survival rate is only 16%3 and 90% with the disease die from it.4 Smoking is the
most important risk factor causing 85% of U.S. lung cancer cases.4 The primary reason
for such a poor cure rate is that nearly all lung cancers are found at a very late stage,
making curative treatment impossible.5 Even with recent advances in detection,
“screening cannot prevent most lung-cancer deaths, and smoking cessation remains
essential.”4, p331

1.2.2 Lung Cancer Screening
An editorial on the status of lung cancer screening6 stressed the need for effective clinical
strategies for aiding patients with lung cancer , which has the highest incidence and
mortality among all cancers. Some groups, for example, the US Lung Cancer Alliance,
advocate use of computed tomography (CT) scan for lung cancer screening. This position
was clearly against the best available screening guidelines (at the time of the present
study) which did not recommend (i.e. cited insufficient evidence for or against7 or
recommended against8) use of CT or chest X-ray (CXR) respectively. Only recently, the
United States Preventative Services Task Force (USPSTF) 2014 Lung Cancer screening
recommendation statement4 updated their 2004 recommendation statement7 to
recommend annual CT Scan for high risk patients. Those at high risk were defined as
asymptomatic current smokers or those who had quit within the last 15 years, and those
between the ages of 55 years and 80 years having a 30 pack per year smoking history.
This guideline was graded as category B meaning “there is high certainty that the net
benefit is moderate or there is moderate certainty that the net benefit is moderate to
substantial.”4, Appendix, Table 1
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The literature reports physician ordering of CXR as a test for lung cancer screening
despite the fact that guidelines were against its use.9 It may be the case that certain patient
factors, such as patient anxiety, diagnosis, or death in close friend or family member, and
patient demands play a vital role in the final decision to order or not order a screening test
for lung cancer.
Research is required to study the behaviour of FPs regarding lung cancer screening and to
explore what factors influence their decision- making. Factors influencing decision
making for cancer screening indicate physician factors, patient factors, and patientphysician relationship are key to finding common ground and lead toward a mutual
decision on whether or not to screen for several cancers.10 However, this model emerged
from studying cancer screening decision-making for cancers such as prostate, colorectal
and breast cancer but did not study lung cancer decision making. The goal of that study
was to understand the decision making process for cancers where National Guidelines
from two or more sources are different.
One study9 utilized a survey questionnaire to explore attitudes, beliefs and behaviours on
lung cancer screening. The researchers concluded that a substantial number of physicians
screen for lung cancer using CXR (25%) despite the fact that it was not recommended.
They also discovered that pulmonologists screen more than family practitioners and those
with more years in practice screen more frequently than those with fewer years in
practice.9 Further research is required to identify the factors that influence decisionmaking for lung cancer screening.
Screening by physicians contrary to the recommended evidence-based guidelines has
potential risks such as increased incidence of false positives, unnecessary investigations,
radiation exposure, psychological stress and increased cost without any benefit.9
It is important to see if the factors affecting decision making for other cancers where
guidelines are conflicting or the evidence is unclear also apply to the case of lung cancer
screening.

4
After many years of research, there is no evidence proving the efficacy of CXR as a
screening test for lung cancer.6 The Memorial-Sloan Kettering11, the Johns Hopkins12 and
the Mayo Lung Project13 trials evaluated CXR as a stand alone screening test or with
sputum cytology to screen for lung cancer. Follow-up did not show a difference in lung
cancer incidence or mortality.11-15
Prevailing national guidelines for lung cancer screening (at the time of the present study)
differed in their advice about the use of CXR. The Canadian Task Force on Preventive
Health Care (CTFPHC) guidelines8 recommended against screening for lung cancer using
CXR and concluded there was insufficient evidence to screen with low-dose computed
tomography (LDCT). The USPSTF stated “the evidence is insufficient to recommend for
or against screening asymptomatic persons for lung cancer with either low-dose
computerized tomography (LDCT), chest x-ray (CXR), sputum cytology, or a
combination of these tests.”7, p738
Nevertheless, in discussions with physician colleagues and departments of radiology, it is
common to find CXR requisitions for asymptomatic patients for annual or periodic
exams, which can be assumed to be for screening purposes. To date, there are no formal
data collected to see whether these tests are being ordered for screening purposes in
Canada. There is limited research regarding factors that may influence physician
screening behaviour on lung cancer screening specifically.9 There have been studies on
physician behaviour on breast, prostate and colorectal cancer.1
Guidelines from various Canadian sources differ in their recommendations for lung
cancer screening. The Saskatchewan Health Services Utilization and Research
Commission16 and British Columbia Council17 recommended against use of CXR.
However the Manitoba Consensus Group18 recommended CXR for screening differing
from the prevailing guidelines for lung cancer screening.
Lung cancer risk among heavy smokers may be as high as 30% 19 compared to nonsmokers. Other risk factors include positive family history of lung cancer20,21 and
a history of chronic obstructive pulmonary disease (COPD).22
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Studies reveal LDCT as a promising screening method for lung cancer detection as part
of periodic health examinations. This could be offered to patients who are identified at
high risk for lung cancer.23 However, the radiation exposure may be harmful.24
The literature does not support lung cancer screening with CXR or with sputum
cytological examination. Risk of inducing anxiety in false positive cases will cause
unnecessary further testing and radiation. Further research is needed for identifying an
appropriate approach to screening in clinic practice.25
Table 1 and 2 summarize the variation in national recommendations for lung cancer
screening at the time of this study.
Table 1-1 National Lung Cancer Screening Guidelines
Screening
Test

CTFPHE

USPSTF

Australia

NHS England

CXR

Recommend Against

Insufficient Evidence

Recommend Against

No Recommendation

CT Scan

Insufficient Evidence

Insufficient Evidence

Recommend Against

No Recommendation

Sputum
Cytology

No Recommendation

Insufficient Evidence

Recommend Against

No Recommendation

Table 1-2 Guidelines from Canadian Sources
Screening
Test

CTFPHE

British
Columbia
Council

Saskatchewan The Manitoba
Health Services Consensus
Utilization and
Research
Commission

CXR

Recommend Against

Recommend Against

Recommend Against

Recommend

CT Scan

Insufficient Evidence

No Recommendation

Recommend Against

Recommend

Sputum
Cytology

No Recommendation

Recommend Against

Recommend Against

Recommend Against

Despite the fact that, with one exception (Manitoba), current recommendations are
against the use of CXR as a screening test for lung cancer, some FPs do screen their
patients.18 These significant variations in recommendations and practice behaviour
identifies a gap and indicates that further research is needed to improve evidence based
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guidelines that are implementable and will improve preventive care in family
practice.18,26

1.2.3 Issues regarding Screening
The literature suggests that a number of factors are involved in decision-making around
screening in general:10,27-29
Physician Perspective:
•

Physicians are a resource to their patients. Physicians prefer to screen, as they like
to prevent life-threatening illness for their patients.

•

Physicians want to be rated as responsible physicians by their communities

•

It is important to build patient-physician relationship

•

Physicians may want to protect against litigation if it will come from not offering
screening tests and by following available best practice guidelines that could
prevent their patients from illness like cancer

Patient Perspective:
•

Patients generally expect their physicians to diagnose illnesses

•

Patients expect their physician to diagnose cancers early by ordering lab tests and
radiological diagnostic tests for their periodic health exams

•

Patients also appreciate and sometimes expect their physicians to educate them
regarding preventative strategies for cancers

Issues regarding Guidelines
•

Several guidelines are available as practice resources

•

Some are conflicting and are unclear

•

Some are clear, however may conflict with physicians practice experience and
don’t take into account the patient’s perspectives.

Need for Screening
•

Saves healthcare dollars by detecting disease early

•

Savings in cost of treatment through earlier diagnosis
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•

Savings in lives saved

•

Savings in ailments and disabilities in relatives and significant others

1.2.4 Physicians’ Attitudes about Screening In General
The literature27 indicates that physicians perform screening tests more often than
recommended or sometimes do not follow current practice recommendations. The
CTFPHC and USPSTF screening guidelines are considered the standard for prevention.
Even when these screening guidelines are thought to be followed, deviation occurs. The
following reasons were identified:27
•

Lack of knowledge of current guidelines.

•

Patient’s expectation or demand as seen in the case of mammography.

•

High volume of patients who are at risk for developing cancer.

•

The physician has concerns regarding the sensitivity and effectiveness of
screening methods.

•

The guidelines that make recommendations also comment on the evidence being
insufficient, which may decrease physician confidence in the recommendation.

•

There is an economic benefit for the physician from ordering frequent tests for
screening.

An American study used online surveys to determine attitudes of physicians regarding
cholesterol and heart disease. It found that most of the physicians surveyed, (who were
from pre-existing independent panels) felt they followed the National Cholesterol
Education Program Adult Treatment Panel III guidelines, but felt that other physicians
did not follow them. The attitudes of physician and consumers were similar in
recognition of the significant health link between cholesterol and coronary artery disease,
but differ in why patients do not take prescription medications.30
With a lack of knowledge about what actually influences physicians’ attitudes toward
screening, an American study examined the influence of actual or perceived state policy
on pediatricians’ attitudes toward screening. It found variations in support for the
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screening guidelines considered in the study. It showed that pediatricians who believed
the State had a policy of screening were more supportive of screening.31
In the absence of literature on the topic, an American study was undertaken to determine
FPs’ knowledge about sexually transmitted infections (STIs) management. The study
demonstrated that physicians with good knowledge of STI guidelines were more likely to
do routine screening of women at high risk for contracting Chlamydia infections. It was
also identified that lack of knowledge was a barrier to following recommended screening
for STIs. Educational and dissemination interventions were recommended.32
A U.S. study found there was substantial variation across medical offices in Chlamydia
screening for at risk women. Further research was suggested to understand predictors of
better office performance with the goal of more effective interventions promoting
screening.33
FPs’ screening practices vary depending on the medical condition being screened and
FPs’ beliefs and practices. A study on FPs’ hepatitis C management found little use of a
standardized history-taking form for disease-specific screening, something shown to be
necessary, to screen for other medical conditions.34
In summary, the literature shows physicians’ screening practices vary and differ from
guideline recommendations. Physician attitudes about screening in general are influenced
by knowledge (or lack thereof), differing recommendations, perceptions of state policy
and sometimes personal preference.

1.2.5 Physician attitude towards Cancer Screening
An Alberta, Canada study explored the attitudes of specialists for colorectal cancer
(CRC) screening practices, the year after a national CRC screening guideline was
released. The results showed specialty-based variations in their practices and significant
overall common practice and personal beliefs/attitudes for self-treatment which went
against the CTFPHE guidelines, in which colonoscopy was not recommended.35 This
might be because specialists see a pre-screened population of patients and screening
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guidelines that might be appropriate for primary care may not necessarily be appropriate
for secondary care.
A U.S. survey study examined physician attitudes to prostate cancer screening at a health
care facility for Veteran Affairs. The survey questionnaire asked what risk factors
influence FP’s' decision to screen patients for prostate cancer. The study concluded FPs
recognized elevated risk for African-Americans and a family history of prostate cancer
but frequently screened elderly or patients with a limited life expectancy, which was not
within guidelines.36
An Italian survey study explored CRC screening knowledge, attitudes and practices of all
general practitioners (GPs) in Lazio, Italy. The response rate was 59%. Ninety four
percent believed CRC was preventable. Knowledge was higher in physicians using
screening guidelines. Twenty-five percent recommended screening tests, 22% did not
recommend and 47% over-recommended. The study investigators felt the low response
rate was indicative of GP’s lack of interest in screening.37
In summary, lack of interest in screening, logistical barriers and a lack of awareness of
cancer information and research services were identified as factors relating to low cancer
screening rates by FPs.

1.2.6 Physicians’ attitudes and practices regarding Lung Cancer
Screening
Physicians’ attitudes and beliefs towards screening for lung cancer have been recently
studied in a U.S. prospective descriptive survey9, mailed to FPs, internists and
pulmonologists. The response rate was 303/3000 (10%) with 71% FPs and 29%
pulmonologists. Physicians were identified as high screeners, low screeners or no
screeners. Physicians were also asked to describe factors that influence ordering of
screening tests.
The study showed the relative importance of factors (highest to lowest) to physicians
when assessing a screening program:
1. If there was proven clinical efficacy
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2. If the test was recommended by USPSTF
3. If randomized control trials improved mortality rate
4. If the test was sensitive
5. If the test was cost effective
Despite the low response rate, the researchers concluded that a substantial number of
physicians screen for lung cancer using CXR (25%) even though guidelines are against
its use as a screening test. Pulmonologists screen more than family practitioners do and
the number of years in clinical practice was directly related to screening behaviour.
“Screening outside accepted guidelines has potential risks including false-positive
results, unnecessary invasive procedures, radiation exposure, psychological stress, and
increased costs to the health care system.”9, Clinical Implications
A large scale U.S. national study38,39 of FPs showed lung cancer screening tests such as
CXR were commonly ordered even though unsupported by guidelines. Other research
shows FPs screen for lung cancer,26,40,41 including one study42 which found 10-90 % of
PCPs reporting they do so.
A U.S. qualitative study of physicians’ lung cancer screening practices used telephoneconducted focus groups.43 Participants consisted of 17 internists and 11 FPs. That study
identified seven factors influencing physicians’ decision to screen for lung cancer: five
physician factors and two patient factors. Physician factors were perception of the
effectiveness of screening; guideline recommendations; practice experience; perception
of patient’s risk factors for lung cancer and fear of litigation. Patient factors were patient
request for screening and ability to pay for the screening procedure.

1.2.7 Physicians’ attitudes towards use of Guidelines
Family physicians play a vital role in cancer screening. The attitudes of family physicians
towards guidelines have been explored. A study by the Ottawa Health Research
Institute44 explored the family physician’s views on cancer screening guidelines. It was
found that guidelines sometimes add controversy and barriers to the decision-making
process. FPs expect guideline developers to provide them with the resources to help in
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their decision-making process by providing clear guidelines in an easy-to-use format on
topics identified by them as relevant to their practice.
Since FPs involve their patients in care, including patient involvement in decisionmaking, FPs expect guidelines/decision-making tools be made available to them in an
interactive format which they can use with their patients in the office setting.44
A German study of general practitioners and internists studied knowledge of secondary
prevention of coronary heart disease. It also studied their perception of guidelines and
how that perception influenced their treatment practices. Results showed that increased
knowledge of guidelines was directly related to improved management of risk factors for
heart disease. However, many physicians who were aware of guidelines chose to treat in
a way that differed from guidelines.45
In a study that assessed knowledge and beliefs of American physicians and how they
influenced their practices in managing colorectal cancer screening, it was found that most
providers recommended screening-guidelines, but patient refusal was common. Usual
practice often did not follow evidence-based guidelines.46
A systematic review of studies on clinician’s attitudes to clinical practice guidelines was
conducted covering years 1990-2000.47 Clinicians agreed guidelines were helpful and
useful as educational tools and believed they tend to improve quality of care. However,
they also found guidelines to be impractical; some felt they were very rigid and
inapplicable to individual patient situations. They also felt guidelines reduced physician
autonomy and were oversimplified. Most expressed the view that guidelines are intended
to cut costs in healthcare. Some also feared that use of guidelines may increase
litigation.47

1.2.8 Influence of Guidelines on Physician Behaviour
Studies have been conducted to understand the influence of guidelines on physician
behaviours and practices. For example, a US survey study was conducted to explore FPs’
attitudes and practices regarding Periodic Health Exam. The study revealed that FPs do
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not follow recommendations to use more selective health care approaches for
prevention.48
Physician factors may affect screening guideline compliance. Compliance with American
Cancer Society CRC screening guidelines was associated with physician’s perception of
risk for CRC in one study.49
A U.S. study assessed the knowledge, perception, and behaviour of family physicians
regarding management of dyslipidemia. The study found variability in all three among
family physicians and also an overall variability in adherence to guidelines.50
All FPs in Newfoundland and Labrador, Canada were surveyed on their prostrate cancer
screening practices, attitudes and continuing medical education (CME) preferences. The
study found physicians were supportive of screening, but their beliefs and practice varied
- one half questioned the reliability and evidence to support digital rectal exam (DRE)
for screening, and one third questioned both DRE and PSA testing, motivating a need for
CME to address identified issues with prostate screening.51
In summary, physicians’ practices vary from one another and may differ from guidelines.
Physicians have a wide variation in knowledge, beliefs and practice patterns. In general,
physicians were supportive of screening, however, their beliefs and practices varied from
guideline recommendations. They also questioned the evidence supporting the guidelines.

1.2.9 Current Evidence about Guidelines for Lung Cancer
Screening
At the time the survey was completed (2012), the prevailing guideline from the Canadian
Task Force on Preventive Health Care (CTFPHC)8 concluded that “there is fair evidence
to recommend against screening asymptomatic people for lung cancer using chest
radiographic examination (D recommendation).”8, p1
The CTFPHC concluded “there is insufficient evidence (in quantity and/or quality) to
make a recommendation as to whether spiral CT scanning should be used for screening
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asymptomatic people for lung cancer. However, other factors may influence decisionmaking. (I recommendation)”8, p1
At the time the survey was completed, the prevailing guideline from the U.S.
Preventative Services Task Force (USPSTF) was the 2004 recommendation for lung
cancer screening, stating that “the evidence is insufficient to recommend for or against
screening asymptomatic persons for lung cancer with either low-dose computerized
tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these
tests.This is a grade I recommendation.”7, p738
The current Cancer Council of Australia health guideline states “No forms of population
screening for lung cancer, including regular chest radiography, with or without sputum
cytology even in high-risk groups, have been shown to improve outcomes and screening
is not recommended. In view of the limited information available on outcome, helical CT
screening for lung cancer is not recommended except in the context of a well- designed
clinical trial.”52, pxiv
In the 2014 update of their 2004 recommendation, the USPSTF4 recommended certain
people at high risk for lung cancer be screened with low dose CT scan annually. The
high-risk people were defined as current smokers or smokers who have quit within the
last 15 years, in adults aged 55-80 who have a 30 pack-year smoking history. A pack year
was defined as smoking an average of one pack of cigarettes per day for one year.
Screening should be discontinued once a person has not smoked for 15 years or
developed a health problem that substantially limits life expectancy or the ability or
willingness to have curative treatment for lung cancer. This guideline was graded as
category B meaning “there is high certainty that the net benefit is moderate or there is
moderate certainty that the net benefit is moderate to substantia.”4, Appendix, Table 1

1.2.10 Post Survey – Recent Literature Summary
Subsequent to survey instrument development and data collection, recent related research
was published. A Scopus search was conducted to bring the literature review up to date.
It found 25 articles that cited Haggerty2, the most recent publication in the series of
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research that this thesis extends2,10,28,53. Three have relevance to physician decision
making. One54 investigated which factors influenced physician decision to order PSA
screening tests. Although factors included some of those studied in this thesis research,
others were dissimilar, and the survey methods and analysis were dissimilar and unsuited
for adaptation or comparison. Another study55 explored which patient and physician
factors influenced cervical cancer screening over and under use. This was not a survey
study, but instead collected actual ordering data. The third study56 involved a survey
instrument completed by both physician and patient regarding attitudes to shared care and
influence on specialist referrals. The instrument and methods were dissimilar to that used
in the current study.
Updates to guidelines for lung cancer screening were also made, with modified
recommendations. The changes have already been discussed in section 1.2.9 above.

1.3 Identification of Research Opportunity
Lung cancer is a prevalent cancer and accounts for significant mortality. There are not
many helpful strategies available for dealing with lung cancer prevention other than
counselling smoking cessation and detection at an earlier stage. There are not many
treatments that are very useful for treating lung cancer. FPs have regular contact with the
patient population at risk for disease and the physician group most likely to screen for
diseases. As their patient population includes smokers, FPs are concerned about them and
face the challenge of what can they do which would be helpful in detecting lung cancer at
early stages.
In summary, lung cancer is a prevalent disease and those at higher risk, such as those who
smoke are frequently attended in family physicians’ offices where screening may be
taking place.
The literature has been reviewed in terms of the effectiveness of lung cancer screening
tests. Recommendations are conflicting regarding use of screening tests. At best, there is
insufficient evidence to recommend routine screening with CXRs. Some guideline panels
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have stated there is enough evidence to say that CXR is not effective and have
recommended against routine screening while others do recommend it.
Regardless, the literature confirms that some FPs do screen with CXRs. There appears to
be a dissonance between what people reviewing the evidence suggest and how certain
FPs are behaving. The literature shows a gap between recommendations and behaviour in
practice and that there is a need to examine some of the various reasons for this gap.
There is also literature that has looked at cancer screening generally and in the context of
uncertainty.38,39,43,57
Therefore, to try to understand this gap, it is important to understand how often FPs
report they are screening for lung cancer, what screening tests they order and the factors
that influence them to behave in a way that is different than some experts have suggested
the evidence would indicate or direct.
Understanding this is important for several reasons. In economic terms, if resources are
being used that are not effective, then they are not available for other purposes. It will
provide insights in terms of helping FPs understand guidelines better and aid in
adherence. It will help guideline developers to understand how they might improve
adherence to recommendations by understanding how intended users make decisions
around screening and the many factors that influence their decision-making.

1.4 Research Questions
The following research questions were explored:
1. What do family physicians practicing in urban and rural Saskatchewan report they
do regarding their lung cancer screening practices?
2. Which lung cancer screening test(s) do family physicians practicing in urban and
rural Saskatchewan report they use?
3. Which factors influence the decision-making of family physicians practicing in
urban and rural Saskatchewan when presented with hypothetical clinical
scenarios?
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1.5 Objectives
The study objectives were:
1. To estimate the frequency with which FPs order lung cancer screening tests. Data
were used to identify two groups of FPs:
a) Screeners, defined as those who report they order lung cancer screening tests for
asymptomatic ever smokers;
b) Non-Screeners, defined as those who report they do not order lung cancer
screening tests for patients who are asymptomatic ever-smokers.
2. To determine how frequently CXR was ordered as a screening test. Since the
CTFPHE recommendations are clearly against the use of CXR as a screening test, the
survey specifically questioned about the use of CXR.
3. To determine the factors that influence lung cancer screening decision-making.
This research explored FPs’ reported lung cancer screening behavior based on factors
identified in the literature that influenced screening decision-making for other cancers
such as breast, colon and prostate. The literature revealed no research to-date that studied
the influence of any of these factors on lung cancer screening decision-making in Canada.
This study incorporates these factors into a proposed model shown in Figure 1-1.
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Patient Factors:
a)
b)
c)
d)

†

Non-Medical Factors:

Patient’s expectation to be screened
Anxiety about having lung cancer
Positive family history of lung cancer
Influence of patient-physician relationship

a)
b)
c)
d)

§

Influence of practice of colleagues
Influence of specialists
Time constraints
Accessibility and cost of test and cost

Order Screening test(s):
□
□
□

Physician Factors:
a)
b)
c)
d)

CXR?
CT Chest?
Sputum Cytology?

‡

Perception of guidelines
Clinical practice experience
Any other factor that influences decision making
Physician demographics
i) Gender
ii) Age
iii) CCFP certification
iv) CFPC membership
v) Years of family practice
vi) Type of practice
vii) Location of practice
viii) Family practice hours
ix) Teaching responsibilities

Where Factors are queried in Survey

†
§

‡

Patient factors are studied in Section II and Section III, Clinical Vignettes.
Non-medical factors are studied in Section II.
Physician factors are studied in Sections I, II and IV.

Figure 1-1 Conceptual FP Lung Cancer Screening Decision Making Model
This illustrates the author’s initial concept of the factors involved in a physician’s lung
cancer screening decision-making based on the literature. It illustrates patient, physician
and non-medical factors that are identified in the literature as factors influencing cancerscreening decision-making for breast, colon and prostate cancers.2,10 This study used
clinic scenarios in the survey to explore whether these factors also influenced lung cancer
decision-making behaviour.
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Chapter 2
Methods
2.1 Introduction
The CTFPHC and USPSTF guidelines for lung cancer screening at the time of the study
differed slightly but none recommended screening with CXR. However, there is
uncertainty about family physicians’ (FPs) lung cancer screening practices in clinical
encounters - whether FPs screen for lung cancer, what screening test do they order and
how often do they screen despite guideline recommendations.
This study identified whether Saskatchewan FPs screen for lung cancer and what factors
influenced them to do so. It consisted of a cross-sectional survey and measured FPs’
responses to self-reported screening behaviour questions and to hypothetical clinical
screening scenarios. These two outcomes were analyzed separately.

2.2 Design
This study consisted of a cross-sectional survey with two components:
1. Questions designed to measure physicians’ self-reported behaviour and
2. Hypothetical clinical scenarios designed to determine physician’s intended
behaviour in different situations. The data collected from these two components
were analyzed separately.

2.3 Sample
The study respondents were FPs practicing in rural, regional and urban areas of
Saskatchewan.
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2.3.1 Inclusion Criteria
Only physicians who worked more than fifteen hours per week in family practice (i.e.
deemed to be full-time) were included. This maintains consistency with the classification
used in comparable research by Tudiver et al.2

2.3.2 Exclusion Criteria
Specialist physicians practicing internal medicine, surgery, pulmonology, neurology,
pathology, radiology and any other specialities were excluded from the study.

2.4 Survey Questionnaire Development
The method of data collection used was survey via a self-administered paper
questionnaire. A mail survey package was developed for distribution, including a letter of
information, a survey questionnaire and a stamped return envelope (Appendices A & B).
This study’s objectives were consistent with Tudiver et al. except that they studied breast,
colon and prostate screening behaviours of FPs whereas this study specifically explored
lung cancer screening behaviour of FPs.
Tudiver’s survey instrument (Appendix C) was adapted because of the benefit of
employing a previously validated methodology. The survey was modified to study lung
cancer screening behaviour. Appendix D describes the systematic and rigorous
adaptations made to the Tudiver survey.

2.5 Variables
2.5.1 Outcomes
Two outcomes were measured:
1. Based on their self-reported screening behaviours, physicians were dichotomized
into Screeners and Non-Screeners. We defined Screeners as physicians who
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ordered screening tests for lung cancer if they reported they routinely ordered
screening tests for asymptomatic patients who are ever-smokers (Section II,
question 2a). Similarly, physicians who reported they did not order lung cancer
screening tests for asymptomatic ever-smokers were defined as Non-Screeners
(Section II, question 2a).
2. Based on their responses to clinical scenarios (Section III), FPs’ intended decision
to order a lung cancer screening test with dichotomous variables (yes or no). This
was based on six hypothetical scenarios:
a) Scenario 1 was considered uncomplicated.
b) Scenarios 2 to 5 each contained a complicating dynamic: expectation, anxiety,
family history, poor patient-physician relationship respectively.
c) Scenario 6 contained all four complicating dynamics.
d) For each scenario, respondents indicated whether they would order any of
three possible screening tests: CXR, CT chest and sputum cytology
2.5.2 Predictor Variables
Several characteristics of the physician and non-medical factors have been shown to
influence physicians’ screening behaviour.10 Therefore the self-reported Screeners and
Non Screeners were compared by the following independent variables:
1. Physician Factors:
a) Physician characteristics (as outlined below) (Section IV):
i.

Gender (question 1)

ii.

Age group (question 2)

iii.

Certification by The College of Family Physicians of Canada (CCFP)
(question 3)

iv.

Professional membership in the College of Family Physicians of Canada
(question 4)

v.

Number of years of family practice (question 5)
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vi.

Type of practice: solo, group (question 6)

vii. Location of practice: urban vs. non-urban-(regional were coded as nonurban (question 7)
viii. Number of practice hours per week (question 8)
ix.

Teaching responsibilities (question 9)

b) Attitudes toward screening (Section II, question 3-13)
c) Perception of guidelines (Section I, questions 1-3)
d) Screening behaviour (Section II, questions 1-2)
2. Non-Medical Factors (Section II, questions 14c-h):
a) Influence of practice colleagues
b) Influence of specialist colleagues
c) Cost of the test
d) Accessibility of test
e) Ease of administration
f) Time constraints
Several patient factors have been identified as the most important determinants of cancer
screening decision-making for breast cancer, colorectal cancer and prostate cancer.10 This
study measured if they also influenced the physicians’ decision to screen for lung cancer
in hypothetical clinical scenarios. These factors were:
1. Patient Factors, self-reported behaviour (Section II, questions 14a-b):
a) Patient’s expectations to undergo screening
b) Anxiety about having lung cancer
2. Patient Factors, measured behaviour (Section III):
a) Patient’s expectations to undergo screening (Scenario 2)
b) Anxiety about having lung cancer (Scenario 3)
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c) Positive family history of lung cancer (Scenario 4)
d) Quality of the patient-physician relationship (Scenario 5)

2.6 Data Collection
A distribution list was generated from the College of Physicians and Surgeons of
Saskatchewan registry and the Regional Health Authority administration offices. A
stratified sample of FPs who met the inclusion criteria were recruited by mailing them a
complete survey package.
To increase the external validity of the study, a high rate of return was desired. The
survey was distributed and administered using methods known to enhance physician
participation. A revised, step-wise Dillman Method58 was used to encourage response:
1. Initial mailing
2. Follow up reminder postcard
3. Second full mailing
4. Phone call reminder

2.7 Data Entry
The Primary Investigator (PI) (author) set up the SPSS data dictionary to correctly code
the item types and values needed. Raw data from each uniquely numbered survey
questionnaire booklet was entered to produce the SPSS database in preparation for
statistical analysis. Some respondents returned partially completed surveys or provided
unexpected multiple responses; all were directly coded as provided. Details of how such
were accommodated are provided in Chapter 3 Results.
Quality was managed by conducting one hundred percent checking. This was jointly
performed post data entry by the PI and an assistant, who compared the coded data with
each survey booklet and reconciled any discrepancies.
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2.8 Data Analysis
Appropriate analysis of the data collected from the survey was done using SPSS
Version 19.
Analysis – Outcome #1
Bivariate analysis examined whether there were any associations between Screeners and
Non-Screeners on physician characteristics, attitudes toward screening, perception of
guidelines and screening behaviour:
Mann-Whitney-U tests were conducted for continuous independent variables and ChiSquare was used for categorical variables.
Analysis – Outcome #2
Analyses were conducted with the outcome of whether to order one of three possible
screening tests in each of the five complicated scenarios. Therefore, 15 comparisons were
made (three possible tests by five possible scenarios); each analysis compared decisions
made in the uncomplicated scenario against the decision made by the same physician in
one of the five complicated scenarios. Due to the repeated nature of the study in that the
same participants were asked to provide their screening responses under different
conditions, McNemar’s Chi square test was used to assess if the proportion that would
screen differed between the each of complicating dynamics (Scenarios 2 to 6) and the
uncomplicated scenario (Scenario 1). Because differences in proportions will be the
result of participants changing their screening practices under the different conditions,
and that these changes can be in either direction (i.e. from “not screen” in the
uncomplicated scenario changing to “screen” in complicated or “screen” in
uncomplicated changing to “not screen” in complicated), it is the net difference in this
change that is statistically important.
Additionally, the influence of recommendation perception on screening behaviour was
assessed. Analyses were conducted comparing the proportion of physicians who would
screen using each test in each of the scenarios against their perceptions of the guidelines
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being recommended or not recommended respectively. Due to the repeated nature of the
study, recognizing that the same participants were assessed concerning their practice
within multiple scenarios, the association between the perception that the test is
recommended and whether or not it was performed was evaluated for each scenario
separately. To account for multiple testing, Bonferroni correction was applied to the
significance level, with 0.05 divided by 6 scenarios to produce a new alpha of 0.008.
Only statistical test results with p-values below this level were considered statistically
significant.

2.9 Reliability and Validity
To ensure validity and to ensure appropriateness of the reading level, the survey was
piloted on three FPs. This was followed by an interview to improve clarity and
comprehensiveness of the questionnaire.
This study also contains a section, consisting of clinical case scenarios where testing is
done in the context of a controlled environment, one where independent variables are
manipulated to examine decision-making behaviour. In this section, the strength of the
internal validity is not felt to be at the expense of external validity; the clinical scenarios
presented are intended to model a real-world clinical encounter.
References on questionnaire design and quality assessment were consulted during
questionnaire development.59-68
To increase the external validity of the study, a high rate of return was desired. This was
promoted in this study by using best practices identified in the literature including
administration of the survey using the step-wise revised Dillman Method, discussed in
Section 2.6 above.

2.10 Ethics Approval
Ethics approval was obtained from the Research Ethics Board of the University of
Western Ontario (Appendix F).
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Chapter 3
Results
3.1 Introduction
This study consisted of a cross-sectional survey of family physicians (FPs) practicing in
Saskatchewan. Of the 250 FPs contacted, 49 responses were deemed acceptable, after
adjusting for surveys which were incomplete on key questions, yielding a final response
rate of 20%. The demographics of the final study participants are presented in Table 3-1
(Questionnaire Section IV); available provincial and national data are also listed for
comparison. In spite of the small sample size and the low response rate, the
characteristics of the study sample are similar to those for Saskatchewan and Canadian
FPs, offering some support for generalizability of the findings. However, the sample has
a higher proportion of female and rural FPs, compared to the provincial or national
populations.
Based on their reported practice behaviour (Section II, question 2a), FPs were divided
into two groups, Screeners and Non-Screeners, defined as:
1. Screeners - those who report they order lung cancer screening tests for
asymptomatic ever-smoking patients;
2. Non-Screeners - those who report they do not order lung cancer screening tests
for asymptomatic ever-smoking patients.
Out of 49 FPs, 34 (69%) were classified as Screeners and 15 (31%) as Non-Screeners. Of
those who screened, CXR was ordered by up to 73% of FPs making it the most
commonly ordered screening test contrary to prevailing guidelines.
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Table 3-1 Physician Characteristics
Physician Factors
All participants
(N = 49)**

Total
Saskatchewan
FP Population
(N = 1089)*†

Total Canadian
FP Population
(N = 34 810)*†

Male
Female

25 (52%)
23 (48%)

(69%)
(31%)

(59.6%)
(40.4%)

<50 years
≥50 years

32 (67%)
16 (33%)

†
†

†
†

CCFP certification, n (%)
Yes
No

24 (50%)
24 (50%)

(51.9%)
(48.1%)

(54.6%)
(45.4%)

CFPC membership, n (%)
Yes
No

44 (92%)
4 (8%)

†
†

†
†

Yes
No

38 (81%)
9 (19%)

(82.2%)
(17.8%)

(78%)
(22%)

Teaching affiliation, n (%)
Yes
No

21 (44%)
27 (56%)

†
†

†
†

Practice location, n (%)
Urban
Rural/regional

25 (52%)
23 (48%)

(55.3%)
(44.7%)

(63%)
(37%)

Practice hours/week,
Mean (SD) ††
Median (IQR) ††

30.8 (13.8)
35 (24, 40)

†
†

†
†

Years in practice
Mean (SD) ††
Median (IQR) ††

13.9 (12.2)
30.8 (13.8)

†
†

†
†

Sex, n (%)

Age, n (%)

Group practice, n (%)

*National Physician Survey 2010, The College of Family Physicians of Canada,
Canadian Medical Association and Royal College of Physicians and Surgeons of Canada
†
Comparable datum not available from National Physician Survey 2010 because it was
either not collected, definitions differ from current study or not reported
**Participants within column may not sum to N due to missing values
††
SD stands for standard deviation, IQR for Interquartile range

27

3.2 Physician Factors and Screening Behaviour
Table 3-2 presents the results for physician factors and compares Screeners and NonScreeners (Questionnaire Section IV). A statistically significant difference was found
where Screeners worked more hours per week than Non-Screeners. Differences were
marginally significant for practice location; Screeners were more likely to be from rural
practices (56%) versus Non-Screeners (29%). There were no statistically significant
differences for the remaining variables.
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Table 3-2 Physician Factors and Screening Behaviour
Physician Factors
All
participants
(N = 49)‡

Screening practices, n (%)*
Screeners
Non(n = 34)
Screeners
(n = 15‡)

pvalue§

Sex, n (%)
Male
Female

25 (52)
23 (48)

18 (53)
16 (47)

7 (50)
7 (50)

<50 years
≥50 years

32 (67)
16 (33)

25 (74)
9 (27)

7 (50)
7 (50)

CCFP certification, n (%)
Yes
No

24 (50)
24 (50)

16 (47)
18 (53)

8 (57)
6 (43)

0.53

CFPC membership, n (%)
Yes
No

44 (92)
4 (8)

30 (88)
4 (12)

14 (100)
0 (0)

0.31**

Yes
No

38 (81)
9 (19)

26 (77)
8 (24)

12 (92)
1 (8)

0.41**

Teaching affiliation, n (%)
Yes
No

21 (44)
27 (56)

13 (38)
21 (62)

8 (57)
6 (43)

0.23

Practice location, n (%)
Urban
Rural/regional

25 (52)
23 (48)

15 (44)
19 (56)

10 (71)
4 (29)

0.09

Number of practice
hours/week,
Mean (SD)
Median (IQR)

30.8 (13.8)
35 (24, 40)

34.9 (10.6)
36 (27.3, 40)

21.0 (16.1)
16.5 (8.3,
36.3)

0.85

Age, n (%)
0.18**

Group practice, n (%)

0.006

Number of years in practice
Mean (SD)
13.9 (12.2)
13.5 (11.6)
14.8 (14.1)
Median (IQR)
30.8 (13,8)
10.5 (3.8, 20)
7 (3.3, 30.3)
0.95
*Denominator is the number of participants responding to the question
‡
Totals within columns do not sum to n due to missing values.
§
p-values comparing Screeners and Non-Screeners’ screening practices for
categorical variables assessed by Chi square test with **Fisher’s exact test where
indicated. Medians for continuous variables compared by Mann-Whitney-U testing.
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3.3 Physician Attitudes & Practices by Screening Group
Table 3-3 compares FPs’ lung cancer screening attitudes and practices by screening
group (Questionnaire Section II, questions 3-13). Participants’ agreement with statements
listed in the table, was dichotomized as yes or no responses. The following discussion of
important findings makes brief mention of the corresponding statements; please refer to
the table for the full statement text.
A significantly larger proportion of Screeners (85%) than Non-Screeners (50%) agreed
with the statement that missing a case of lung cancer would result in increased screening
for some time afterwards.
Similarly, a significantly larger proportion of Screeners (67%) than Non-Screeners (21%)
agreed with the statement that they would routinely screen if there was a positive family
history of lung cancer.
A significantly larger proportion of Screeners (88%) than Non-Screeners (57%) agreed
with the statement that they would routinely screen if there was occupational exposure
such as asbestos, silica and chemicals.
A significantly larger proportion of Screeners (79%) than Non-Screeners (29%) agreed
with the statement that they would routinely screen if there were co-morbid conditions
such as COPD
A significant minority of Screeners (13%) and a majority of Non-Screeners (79%) agreed
with the statement that they would not recommend CXR for screening because they
thought there was potential to cause more harm than good.
Medico-legal considerations had no impact on screening behaviour among FPs in either
group.
Both Screeners and Non-Screeners were equally likely to apply lung cancer guidelines to
each individual patient’s needs.

Table 3-3 Physicians’ agreement with statements on attitudes and practices by screening group
Statement

Agreement
Screeners
n = 34

Non-Screeners
n = 15

p-value†

Yes
n (%)*

No
n (%)*

Yes
n (%)*

No
n (%)*

The guidelines for lung cancer screening are just
guidelines.

27 (82)

6 (18)

14 (100)

0 (0)

0.16

I apply lung cancer screening guidelines to each individual
patient’s needs.

25 (76)

8 (24)

11 (79)

3 (21)

1.0

I tend to follow lung cancer screening guidelines when they
are published by an organization that I trust.

31 (94)

2 (6)

12 (86)

2 (14)

0.57

If I missed a case of lung cancer I would tend to screen
more patients for that particular disease for some time
afterwards.

28 (85)

5 (15)

7 (50)

7 (50)

0.03

I will routinely recommend a lung cancer screening test
when there is insufficient evidence, in order to avoid
medical-legal repercussions.

7 (21)

26 (79)

2 (15)

11 (85)

1.0

I will routinely recommend a lung cancer screening test for
patients if there is a positive family history of lung cancer

22 (67)

11 (33)

3 (21)

11 (79)

0.009

I will routinely recommend a lung cancer screening test for
asymptomatic patients when there is a history of
occupational exposure to asbestos, silica, or other
chemicals.

29 (88)

4 (12)

8 (57)

6 (43)

0.046
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Statement

Agreement
Screeners
n = 34

Non-Screeners
n = 15

p-value†

I will routinely recommend a lung cancer screening test
when patients have co-morbid conditions such as COPD.

26 (79)

7 (21)

4 (29)

10 (71)

0.002

I do not recommend CXR for lung cancer screening
because I think it has the potential to cause more harm
than good.

4 (13)

28 (88)

11 (79)

3 (21)

<0.0001

I do not recommend CT Chest for lung cancer screening
because I think it has the potential to cause more harm
than good.

20 (63)

12 (38)

10 (71)

4 (29)

0.74

*Denominator is the number of participants responding to the question.
p-values comparing Screeners and Non-Screeners screening practices for categorical variables assessed by Fisher’s
exact test due to frequent small expected cell sizes.
Number of responses to a specific statement within the groups may not sum to group total due to missing values.
Percentages may sum to more than 100% due to rounding.
†
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3.4 Physicians’ Perceptions of Lung Cancer Screening
Guidelines
Table 3-4 reports FPs’ perceptions of lung cancer screening guidelines (Questionnaire
Section I). There was a statistically significant difference in that Screeners were more
likely (52%) than Non-Screeners (7%) to perceive that CXR was recommended for their
smoking patients. There were no statistically significant differences for the remaining
variables. Of note, Screeners (69%) and Non-Screeners (46%) found the guidelines for
lung cancer screening for asymptomatic smokers to be unclear.

33

Table 3-4 Perceptions of Lung Cancer Screening Guidelines

All (N=49**)

Screeners
(n=34**)

NonScreeners
(n=15**)

6 (12)
43 (88)

6 (18)
28 (82)

0 (0)
15 (100)

0.16

CT scan
Recommended, n (%)
Not recommended, n (%)

2 (4)
47 (96)

2 (6)
32 (94)

0 (0)
15 (100)

1.0

Sputum cytology
Recommended, n (%)
Not recommended, n (%)

4 (8)
45 (92)

3 (9)
31 (91)

1 (7)
14 (93)

1.0

For ever-smokers
CXR
Recommended, n (%)
Not recommended, n (%)

18 (38)
30 (62)

17 (52)
16 (49)

1 (7)
14 (93)

0.003

CT scan
Recommended, n (%)
Not recommended, n (%)

7 (15)
41 (85)

6 (18)
27 (82)

1 (7)
14 (93)

0.41

Sputum cytology
Recommended, n (%)
Not recommended, n (%)

9 (18)
40 (82)

8 (24)
26 (77)

1 (7)
14 (93)

0.24

Guideline Perception
by test
n (%)‡
For never-smokers
CXR
Recommended, n (%‡)
Not recommended§, n (%)

p-value†

Clear guidelines for eversmoking patients, n (%)
17 (38)
10 (31)
7 (54)
0.19
Yes, n (%)
28 (62)
22 (69)
6 (46)
No, n (%)
†
p-value comparing Screeners and Non-Screeners screening practices assessed by
Fisher’s exact test due to frequent small expected cell sizes.
‡
Denominator for all percentages is the number of participants responding to the question
§
Not recommended responses to all questions include “recommended against”,
“insufficient evidence” and “conflicting guidance”
**Participants within columns may not sum to N or n due to missing values
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3.5 Choice of Screening Test among Screeners by
patient’s smoking status
Table 3-5 reports the choice of screening tests (Questionnaire Section II, questions 1 b
and 2 b) among Screeners. Since the criterion for Screeners and Non-Screeners was
based on whether or not FPs screen asymptomatic, ever-smoking patients, FPs in the
Screener group will all indicate that they screen these patients while Non-Screeners by
definition will not have screened, and, unsurprisingly, all of them indicated that they
would not screen never-smokers either. Among Screeners, 16 of the 34 FPs (47%) also
screened never-smokers. So although Screeners are more likely to indicate at least some
degree of screening among never-smokers compared to Non-Screeners, the data suggest
that this tendency is still considerably less than when evaluating ever-smokers (100%).
Among Screeners, CXR was the most frequently ordered test (97%) for ever smoking
patients and (94%) for never smoking patients.
Table 3-5 Choice of Screening Test by Smoking Status among Screeners
(n=34)
Never-smokers
(Section II Q 1 b)

Ever-smokers
(Section II Q 2 b)

CXR, n (%)
Yes
No
Would not screen

15 (94)
1 (6)
18*

33 (97)
1 (3)

CT, n (%)
Yes
No
Would not screen

0 (0)
16 (100)
18*

2 (6)
32 (94)

Screening Test

Sputum, n (%)
Yes
5 (31)
8 (24)
11 (69)
26 (77)
No
Would not screen
18*
*Out of 34 Screeners(FPs who will order screening test in ever-smoking patients) 18 did not
report ordering screening tests in never-smoking patients
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3.6 Influence of Non-medical Factors on Screening
Behaviour
Table 3-6 reports the influence of non-medical factors on screening behaviour
(Questionnaire Section II, questions 14a-14h). Results were not statistically different for
the variables but approached marginal significance in their screening behaviour if the test
was easily accessible or if the test was easy to administer, Screeners more frequently
order screening tests (77%) than Non-Screeners (50%).
Table 3-6 Physician agreement that non-medical factors would influence
test ordering behaviour
Statement

Screeners
n = 34

Non-Screeners pn = 15
value†

Yes
n (%)

No
n (%)

Yes
n (%)

No
n (%)

A patient is anxious about having the
disease

29 (85)

5 (15)

9 (69)

4 (31)

0.24

A patient requests the test and insists on
having it done

32 (94)

2 (6)

12 (86) 2 (14)

0.57

I hear that my colleagues are
recommending it to their patients

9 (27) 25 (74)

2 (14) 12 (86) 0.47

Specialists I work with recommend
ordering the test

26 (77)

8 (24)

12 (92)

1 (8)

0.41

The test is inexpensive

21 (62) 13 (38)

6 (43)

8 (57)

0.34

The test is easily accessible

26 (77)

8 (24)

7 (50)

7 (50)

0.09

The test is easy to administer

26 (77)

8 (24)

7 (50)

7 (50)

0.09

The test will take less time to order than to 14 (41) 20 (59)
convince a patient they do not need it

5 (36)

9 (64)

1.0

†

p-values comparing Screeners and Non-Screeners’ screening practices for categorical variables
assessed by Fisher’s exact test due to frequent small expected cell sizes.
Number of responses to a specific statement within the groups may not sum to group total due to
missing values.
Percentages may sum to more than 100% due to rounding.
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3.7 Influence of Lung Cancer in Self or Close Relative
and Smoking on Screening Behaviour
Table 3-7 reports the influence of a lung cancer diagnosis for physician personally or for
someone close or of smoking status on screening behaviour (Questionnaire Section V,
questions 1-3).
There were no statistically significant differences between Screeners and Non-Screeners
in the proportion who had experienced a diagnosis of lung cancer themselves or anyone
close to them. This response could not be further assessed by smoking status since 29 out
of 51 participants answered both questions as smoker and as non-smoker and as such
could not be clearly assigned as either smoker or non-smoker.
Table 3-7 Close experience with lung cancer and smoking status
All
participants
N = 49

Screeners
n = 34†

NonScreeners
n = 15†

p-value‡

13 (27)
35 (73)

11 (32)
23 (68)

2 (14)
12 (86)

0.29

Yes
5 (11)
5 (15)
0 (0)
41 (89)
28 (85)
13 (100)
No
†
Participants within columns may not sum to n due to missing values.
‡
Fisher’s exact test

0.30

Have you or anyone close to
you ever been diagnosed with
lung cancer? n (%)
Yes
No
Would seek screening for self,
n (%)
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3.8 Influence of Patient Factors in Clinical Vignettes
Table 3-8 reports the proportion of participants who indicated they would screen for each
of the six scenarios (Questionnaire Section III). CXR was the most frequently ordered
test.
Table 3-8 Proportions of participants screening using CXR, CT, or sputum
cytology in uncomplicated and complicated scenarios
n (%)
CXR
Uncomplicated Scenario
No complications
Complicating dynamic
Expectation
Anxiety
Family History
Poor relationship
All four dynamics
CT Chest
Uncomplicated Scenario
No complications
Complicating dynamic
Expectation
Anxiety
Family History
Poor relationship
All four dynamics
Sputum cytology
Uncomplicated Scenario
No complications
Complicating dynamic
Expectation
Anxiety
Family History
Poor relationship
All four dynamics

23 (48%)
21 (44%)
28 (58%)
30 (63%)
23 (48%)
35 (73%)

3 (6%)
2 (4%)
3 (6%)
3 (6%)
2 (4%)
8 (17%)

9 (19%)
6 (13%)
5 (10%)
7 (15%)
6 (13%)
8 (17%)
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3.9 Influence of Patient Factors in Clinical Vignettes
Table 3-9 compares the proportion of participants who screened in the uncomplicated
scenario (Scenario 1) with each of the complicated scenarios (Scenario 2 – 6). The
purpose of the analysis is to determine if the factor(s) introduced in each scenario
significantly affects the decision to order each lung cancer screening test. The p-value
shown indicates if there is a statistically significant effect due to the introduction of this
factor. It is computed using the McNemar test for matched pairs of data, in this case the
comparison of results for the uncomplicated scenario with each of the complicated
scenarios. Note that participants are not divided into the previous Screener/Non-Screener
categories. The table divides participants into two groups, those who screened in the
uncomplicated scenario and those who did not. Within each group, results are further
subdivided into those who would/would not screen to make it easier to see changes in
behaviour between the scenarios and groups.
A walkthrough will be presented to make this clearer. The first set of yes and no values
indicate that 23 participants said they would screen using a CXR in the uncomplicated
scenario (Scenario 1), while 25 participants said they would not. So based on this
response, the respondents were divided in two groups; Uncomplicated Screeners and
Uncomplicated Non-Screeners.
We then looked at the responses of Uncomplicated Screeners to see what they would do
in complicated scenarios. We found that if the patient expects the test, 15 of the 23 (65%)
that did screen in Scenario 1 would also screen when the complicating dynamic
expectation was added (Scenario 2), while 8 (35%) would not.
Similarly, among the 25 participants who indicated they would not screen in the
uncomplicated situation, 6 (24%) now would screen when the patient expects the test as
in Scenario 2. However, 19 participants (76%), did not change their position and would
not screen whether the patient expected the test or not.
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So the question is, does adding the dynamic of expectation to the patient- physician
interaction change the proportion of participants who would screen? To assess this, our
interest is in those who change their screening decisions between the two scenarios. On
the left hand side we see that, when we add the element of expectation (Scenario 2), 8 of
the 23 participants (35%) who would have screened in Scenario 1 choose not to screen
with a CXR in Scenario 2, while 6 of the 25 participants who would not have screened in
Scenario 1 (right side), choose to screen in Scenario2. The McNemar statistic examines
the difference in the choices made in each of these scenarios. In case of Scenario 2 versus
Scenario 1, there is no statistically significant change in choices (p-value=0.79. As such
we can draw no overall conclusion about the impact of patient expectation on screening
decisions – in some it appears to decrease the tendency to screen, while in others it seems
to increase it.
Similarly, the results do not show a statistically significant change with the addition of
complicating dynamics of anxiety, family history or poor relationship are added as
individual complicating dynamics in each of the scenarios. We do however, find the
results to be clinically relevant as 40% participants who did not screen in Scenario 1
indicated they will screen if positive family history was added (Scenario 4)
Results show a statistically significant difference for participants’ responses in the
uncomplicated scenario (Scenario 1) compared to responses for the multiple dynamic
scenario (Scenario 6) p-value=0.006.
There is no statistically significant indication that FPs will change their screening
practices with chest CT or sputum cytology when the dynamics of patient expectation,
patient anxiety, family history, or poor patient-physician relationship are present
compared to when they are not. Overall it appears that FPs are generally unlikely to
screen ever-smokers with chest CT under any scenario situations.

Table 3-9 Comparison of the proportions of participants screening using CXR, CT, or sputum cytology in
uncomplicated versus complicated patient-physician interactions
CXR

Complicating dynamic
Expectation
Anxiety
Family History
Poor relationship
All four dynamics

CT Chest

Complicating dynamic
Expectation
Anxiety
Family History
Poor relationship
All four dynamics

Screen in uncomplicated scenario
Yes, n = 23 (48%)
No, n = 25 (52%)
Screen in complicated scenario
Yes
No
Yes
No
15 (65%)
21 (91%)
20 (87%)
18 (78%)
21 (91%)

8 (35%)
2 (9%)
3 (13%)
5 (22%)
2 (9%)

6 (24%)
7 (28%)
10 (40%)
5 (20%)
14 (56%)

19 (76%)
18 (72%)
15 (60%)
20 (80%)
11 (44%)

Screen in uncomplicated scenario
Yes, n = 3 (6%)
No, n = 45 (94%)
Screen in complicated scenario
Yes
No
Yes
No
1 (33%)
2 (67%)
2 (67%)
1 (33%)
1 (33%)

2 (67%)
1 (33%)
1 (33%)
2 (67%)
2 (67%)

1 (2%)
1 (2%)
1 (2%)
1 (2%)
7 (16%)

44 (98%)
44 (98%)
44 (98%)
44 (98%)
38 (84%)

p-value*
0.79
0.18
0.09
1.0
0.006

p-value*
1.0
1.0
1.0
1.0
0.18
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Sputum cytology

Complicating dynamic

Screen in uncomplicated scenario
Yes, n = 9 (19%)
No, n = 39 (81%)
Screen in complicated scenario
Yes
No
Yes
No

p-value*

Expectation
5 (56%)
4 (44%)
1 (3%)
38 (97%)
0.38
Anxiety
5 (56%)
4 (44%)
0 (0%)
39 (100%)
0.13
Family History
5 (56%)
4 (44%)
2 (5%)
37 (95%)
0.69
Poor relationship
4 (44%)
5 (56%)
2 (5%)
37 (95%)
0.45
All four dynamics
7 (78%)
2 (22%)
1 (3%)
38 (97%)
1.0
*McNemar’s test comparing the proportion of participants who would screen in the uncomplicated scenario to the
proportion screening in each of the complicated scenarios
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3.10 Proportion of participants screening within each
scenario by perception of screening
recommendation
Table 3-10 reports on the influence of perception of screening guideline
recommendations on screening decision making. For this analysis, the significant p-value
was set at 0.008 to account for multiple testing. In scenarios where the patient-physician
interaction was uncomplicated, patients expected the test, or patients had a family history
of disease, participants were statistically significantly more likely to screen with a CXR if
they perceived that it was recommended than if it was not. Recommendations did not
clearly change screening practice if the patient was anxious, had a difficult relationship
with the physician, or had multiple dynamics, as participants who did not perceive the
test as recommended often showed some tendency to screen under these conditions.
From the group of FPs who did not perceive CXR was recommended and did not screen
(21), a clinically significant number of them were influenced to screen if the patient was
anxious or there was a positive family history of disease (for each factor, an increase
from 8 to 13 out of 21, 63%) and with multiple dynamics (an increase from 8 to 19 out of
21, 138%).
So we can conclude that perception of recommendations influences FPs decision-making
for lung cancer screening with CXR. However, when faced with patient factors of
anxiety, difficult relationship and multiple complicating factors FPs decision to screen
over-rides their perception meaning that these factors influence their decision-making.
Perception of recommendation regarding screening with CT did not appear to make a
difference as to whether participants would screen or not. Although 7 individuals
indicated that they felt CT is recommended as a screening tool in ever-smokers, its use
was infrequently indicated in the scenarios.
Perception of recommendation regarding screening with sputum cytology appeared to
make a difference in all scenarios as to whether or not a FP decided to screen. In each
scenario approximately half to two-thirds of the nine FPs who felt that screening with
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cytology in ever-smokers is recommended indicated that they would screen, while less
than 10% of those who felt that cytological screening was not recommended, indicated
they would order it. This contrast was statistically significant in all comparisons
regardless of the presenting dynamic.

Table 3-10 Proportion of participants screening within each scenario by perception of screening recommendation

Uncomplicated
Expectation

Screen, n (%)
Yes
No
23 (48)
25 (52)
21 (43)
27 (57)

Perceived as
recommended, n=18
Screen, n (%)
Yes
No
14 (78)
4 (22)
14 (78)
4 (22)

Not perceived as
recommended, n=29
Screen, n (%)
Yes
No
8 (28)
21 (72)
7 (24)
22 (76)

Anxiety
Family history
Poor relationship
All four dynamics

28 (58)
30 (62)
23 (48)
35 (73)

14 (78)
16 (89)
12 (67)
15 (83)

13(45)
13 (45)
10 (34)
19 (66)

Overall N=48*
CXR

20 (42)
18 (38)
25 (52)
13 (27)

16 (55)
16 (55)
19 (66)
10 (34)

Overall N = 48*

Perceived as
recommended, n=7

Not perceived as
recommended, n=40†

Screen, n (%)
Yes
No
3 (6)
45 (94)
2 (4)
46 (96)
3 (6)
45 (94)
3 (6)
45 (94)
2 (4)
46 (96)
8 (17)
40 (83)

Screen, n (%)
Yes
No
1 (14)
6 (86)
0 (0)
7 (100)
1 (14)
6 (86)
1 (14)
6 (86)
1 (14)
6 (86)
2 (29)
5 (71)

Screen, n (%)
Yes
No
2 (5)
38 (95)
2 (5)
38 (95)
2 (5)
38 (95)
2 (5)
38 (95)
1 (3)
39 (97)
6 (15)
34 (85)

Chest CT

Uncomplicated
Expectation
Anxiety
Family history
Poor relationship
All four dynamics

4 (22)
2 (11)
6 (33)
3 (17)

p-value†

0.001
0.001
0.04
0.005
0.04
0.32
p-value

0.39
1.0
0.39
0.39
0.28
0.59
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Overall N = 48*

Perceived as
recommended, n=9

Screen, n (%)
Yes
No
9 (19)
39 (81)
6 (12)
42 (88)
5 (10)
43 (90)
7 (15)
41 (85)
6 (12)
42 (88)
8 (17)
40 (83)

Screen, n (%)
Yes
No
6 (67)
3 (33)
5 (56)
4 (44)
4 (44)
5 (56)
5 (56)
4 (44)
6 (67)
3 (33)
6 (67)
3 (33)

Sputum cytology

Uncomplicated
Expectation
Anxiety
Family history
Poor relationship
All four dynamics

Not perceived as
recommended, n=39
Screen, n (%)
Yes
No
3 (8)
36 (92)
1 (3)
38 (97)
1 (3)
38 (97)
2 (5)
37 (95)
0 (0)
39 (100.0)
2 (5)
37 (95)

p-value

0.0005
0.0004
0.003
0.001
<0.0001
0.0002

*One participant did not provide a response to the vignette questions; among the remaining 48, two did not state their
perception of CXR and CT respectively in ever-smokers;
†
p-values from Fisher’s exact test due to frequent small expected cells sizes and α = 0.008 to compensate for multiple
comparisons (0.05/6 scenarios).
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3.11 Conclusions
Results showed a substantial variation in reported lung cancer screening behaviour
among FPs. Participants were classified as Screeners (69%) or Non-Screeners (31%)
based on whether or not they reported ordering screening tests for their asymptomatic
ever-smoker patients. Among Screeners, 16 of the 34 FPs (47%) also screened neversmokers.
Screeners were more likely to work more hours per week than Non-Screeners but were
otherwise not distinguishable with respect to gender, age, College Certification or
membership, type of practice, practice location or teaching affiliation.
Despite the fact that national guidelines did not recommend CXR as a screening test, it
was the most frequently ordered test.
Missing a case of lung cancer resulted in increased screening behaviour for some time
afterwards in both Screeners (85%) and Non-Screeners (50%). Similarly, a positive
family history of lung cancer, occupational exposure such as asbestos, silica and
chemicals or presence of comorbid conditions such as COPD resulted in a statistically
significant difference in screening behaviour in Screeners (67%) and Non-Screeners
(21%).
A minority of Screeners (13%) and a majority of Non-Screeners (79%) did not
recommend CXR for screening because they thought there was potential to cause more
harm than good. Medico-legal considerations had no impact on screening behaviour
among FPs in either group.
Both Screeners and Non-Screeners were equally likely to apply lung cancer screening
guidelines to each individual patient’s context.
Screening behaviour was influenced in favour of screening if the test was easily
accessible or if the test was easy to administer, Screeners (77%) and Non-Screeners
(50%).
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Thirty-nine percent of FPs perceived CXR was recommended for lung cancer screening
even though the prevailing guidelines at the time of data collection did not recommend
CXR as a lung cancer screening test. It is interesting to note that both Screeners and NonScreeners found the guidelines for lung cancer screening for asymptomatic ever smokers
to be unclear.
It is worth noting that 18 participants thought CXR was recommended, but when faced
with a scenario, 23 actually ordered one. Their responses changed when the question was
one about recommended guidelines or a hypothetical case scenario suggesting that patient
factors are a major influence on FP screening decision-making behaviour.
The fact that 48% screened in the uncomplicated scenario contrary to prevailing national
guidelines, suggests that there must be other factors (besides the complicating dynamics
assessed in this study) influencing their decision-making.
Among the participants who would not screen in the uncomplicated scenario, some
indicated they will screen in the presence of additional factors (expectation, anxiety,
family history, poor relationship) indicating that these factors influence their decisionmaking.
FPs’ decision making is influenced by their perception of guidelines, however the
presence of certain patient factors over rides their perception and influences their
decision-making.
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Chapter 4
Discussion
4.1 Introduction
This study made several important findings regarding the lung cancer screening practices
and decision-making of family physicians (FPs) practicing in urban and rural
Saskatchewan. First, the results showed a substantial variation in the reported lung cancer
screening behaviour of FPs, both in their decision to screen and choice of screening test,
with a majority of participants reporting they screened for lung cancer. Second, chest Xray (CXR) was the most commonly ordered screening test. Third, based on whether or
not they reported ordering screening tests for their asymptomatic ever-smoker patients,
69% were classified as Screeners. Fourth, clinical decision-making was assessed via
clinical vignettes; the results demonstrated that up to 73% of FPs would order CXR for
screening, contrary to prevailing guidelines. A significant number of FPs indicated they
would screen in response to multiple patient factors (expectation, anxiety, family history,
poor patient-physician relationship) in contrast to an uncomplicated patient scenario. This
was true even for FPs who had indicated in another question that they perceived the
guidelines to be against screening.
This study is unique, the first study regarding lung cancer screening in Canada. It
contributes to the literature about existing FPs’ practices and decision-making regarding
lung cancer screening and highlights implications to health care cost, patient care, CME
initiatives, and clinical practice guidelines.

4.2 Physician Factors and Screening Behaviour
Screeners were more likely to work more hours per week than Non-Screeners but were
otherwise not distinguishable with respect to sex, age, college certification or
membership, type or location of practice, teaching affiliation or number of years of
practice. This is similar to what Tudiver et al found,2,53 in that all of the above-mentioned
factors did not significantly influence primary care physicians’ (PCPs) screening
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decisions for breast, colorectal and prostate cancer. However, recent studies on lung
cancer screening by PCPs found increased screening was associated with physicians
having more than 10 years in practice in one study9, and in another more than 20 years39.
A larger sample size might demonstrate similarities or differences between Screeners and
Non-Screeners, thereby permitting further comparison with the findings of other studies.

4.3 Influence of Physician Attitudes on Screening
Behaviour
Some statistically significant differences were found between Screeners and NonScreeners when asked if they would screen in the presence of potentially influential
physician or patient factors (one factor per question).
Screeners were more likely to be influenced to screen than Non-Screeners by one
physician factor and by three patient factors. Missing a case of lung cancer influenced
FPs stated behaviour to increase screening. This result is consistent with the influence of
this physician factor in Tudiver`s qualitative study10 for other cancers. Similarly, positive
family history, occupational exposure such as asbestos, silica and chemicals, and the
presence of comorbid conditions such as COPD resulted in increased screening
behaviour. These patient factors consist of known risks for developing lung cancer other
than by smoking.7 The positive influence of these factors on screening can be explained
by Screeners using evidence-based decision making for a population at risk (ignoring
issues surrounding choice of screening test).
Non-Screeners (79%) were more likely than Screeners (13%) to not recommend CXR for
screening due to the belief that it had the potential to cause more harm than good. The
strong influence for Non-Screeners is consistent with evidence-based decision making
informed by risk of potential harm.7 This physician factor is consistent with its
identification by Tudiver10. However, it was found to have a relatively weak screening
influence for screening using PSA and mammograms in Tudivers’ survey.53
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4.4 Physicians’ Perception of Lung Cancer Screening
Guidelines
Screeners were more likely (52%) than Non-Screeners (7%) to perceive that CXR was
recommended for their smoker patients. Yet, there are no guidelines, which recommend
use of CXR as screening test under any patient conditions. It is interesting to note that
both Screeners (69%) and Non-Screeners (46%) found the guidelines for lung cancer
screening for asymptomatic ever smokers to be unclear. The results of this study
demonstrate wide variation in lung cancer screening practices between FPs and frequent
ordering of tests not recommended in national guidelines. It is important to address this
variation as well as other guideline discordant practices as they have significant,
unnecessary clinical and cost implications.69-71 As an example, guideline discordant care
for lung cancer in elderly patients results in poor survival outcomes.72 Unnecessary tests
may cause avoidable radiation exposure and anxiety that may be induced by false
positive results.7
In part, these results imply a gap in knowledge with respect to lung cancer screening
guidelines. The survey item which collected these data directly measured perception, not
knowledge. It was not possible to know in advance which of potentially many
guideline(s) the respondent was informed by, so direct questioning about knowledge of a
specific guideline or guidelines would be premature and outside the scope of the study.
Asking about perception also avoided potential risk of non-response if a participant felt
he/she was being tested/assessed on specific guideline knowledge. None the less, even
though the survey item measured perception, it also indirectly measured knowledge,
finding some knowledge gaps with respect to related parts of a specific guideline. This
was true for the perception that guidelines recommended CXR for smoker patients, when
no major guidelines did so. This finding highlights one significant gap, but are there
others? More comprehensive research, measuring detailed knowledge of specific
guidelines would be valuable and necessary to find all the gaps. They could then be
addressed by revised guidelines, arranging CME training, or publishing guidelines in
journals. To allow access and wider dissemination, guidelines for lung cancer screening
can be made part of the electronic medical record (EMR).44
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Future research should explore why FPs order CXR as a screening test, especially among
those who perceived guidelines did not recommend using CXR as a lung cancer
screening test. This could be achieved by conducting qualitative research, either in-depth
interviews or focus groups.
Both Screeners and Non-Screeners were equally likely to state that they apply lung
cancer guidelines to each individual patient’s context consistent with findings in
literature.73,74

4.5 Choice of Screening Test among Screeners
Screeners comprised 69% of FPs. Among these Screeners, 47% also screened neversmokers.
CXR was the most frequently ordered lung cancer screening test, reported by 67% of
FPs, despite the fact that national guidelines did not recommend CXR for this purpose.
This was confirmed by the results from clinical scenarios with multiple dynamics
(Scenario 6), where 35 out of 48 FPs (73%) said they would screen using CXR. This
seems to indicate a higher prevalence than reported in a prior U.S. study, which utilized a
survey questionnaire to measure attitudes, beliefs and behaviour for lung cancer
screening. It concluded that a substantial number of physicians (amongst FPs and
pulmonologists) reported they screen for lung cancer using CXR (25%) despite the fact
that it was not recommended.9
The question about why FPs order CXR screening tests remains unanswered. Since a
surprisingly large number of participants indicated they screen using CXR in this study,
further research to identify the factors that influence decision- making for lung cancer
screening should be conducted. A qualitative research design can explore this in future.
This knowledge will help to address the frequency of its use as it results in unnecessary
investigations and has unnecessary cost implications69,70 without any return in improved
health care delivery.
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4.6 Influence of Non-medical Factors on Screening
Behaviour
Screening behaviour was influenced in favour of screening if the test was easily
accessible or if the test was easy to administer. This finding did not reach statistical
significance but was a clinically relevant difference that in a larger sample may have been
significant. This finding may help to shed some light on why FPs did not report ordering
a CT scan and sputum cytology at a high frequency. It might be that CXR was the most
ordered screening test because of its availability at most rural, regional and urban sites.
CXR might also be ordered as a baseline comparison reference, believed to be an
inexpensive way to detect potential lung cancer via abnormal changes in subsequent
images.5 CT Scanners are not available in rural facilities and radiologists at regional sites
may refuse tests for screening purposes because of staffing issues or may triage as a CT
that can be done several months later. It may also be that FPs offer CT chest as a
screening test but patients refuse it to avoid driving or because some of them may be
dependent on family members living at remote sites. As well, sputum cytology may yield
high false negative tests and it may be that FPs consult pulmonologists for bronchoscopy
and sputum cytology instead of ordering it themselves.

4.7 Influence of Lung Cancer in Self or Anyone Close
and Smoking Status on Screening Behaviour
There were no statistically significant differences between Screeners (32%) and NonScreeners (14%) based on themselves or close relatives having lung cancer on screening
behaviour. These results are consistent with the Tudiver survey53 which did not report
significant influence. Note that this physician factor was represented in the current study
population, reported by (27%) participants, with the larger proportion being Screeners. A
larger sample size might demonstrate similarities or differences between Screeners and
Non-Screeners.
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4.8 Influence of Patient Factors in Clinical Scenarios
Section III of the survey consisted of the vignette-based study, which explored
participants’ intended behaviour under the influence of patient factors also called
complicating scenarios. The outcome was the decision to order one or more types of lung
cancer screening tests in each scenario. The goal was to discover the influence of these
factors on FPs’ decision-making.
Results for clinical scenarios for the baseline uncomplicated scenario (Scenario 1)
showed 48% of participants would order a CXR to screen for lung cancer. The results
showed a statistically significant increase in the screening behaviour in the presence of
multiple patient factors (Scenario 6 – all four dynamics) p=0.006. When positive family
history was added as complicating factor, the results showed a clinically relevant increase
in CXR screening behaviour. Only a larger study would determine whether these trends
are statistically significant.
On the other hand, non-screeners in the uncomplicated scenario showed a tendency to
increase screening in each complicated scenario with statistical significance found when
all four dynamics were in play. The non-screeners in the uncomplicated scenario seem to
be leaning toward screening when complicating dynamics are added while the screeners
in uncomplicated scenario leaned in the opposite direction. Only a larger study would
determine whether these trends are statistically significant. If they are, further qualitative
research might address the differences in approach to their practice.
There were no statistically significant indications that FPs will change their screening
practices with chest CT or sputum cytology when the dynamics of patient expectation,
patient anxiety, family history, or poor patient-physician relationship are present
compared to when they are not. Overall, it appears that FPs were generally unlikely to
screen ever-smokers with chest CT under any scenario. It is interesting to note, however,
that only approximately half of the nine participants who would have screened using
sputum cytology in the uncomplicated scenario would not do so in more complex
situations. Further research might explore the rationale behind this observation.
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FPs were more likely to make decisions according to their perception of guidelines as
was observed in the responses for the uncomplicated scenario (Scenario 1) and in the
presence of patient expectation (Scenario 2) and family history (Scenario 3) for CXR and
in all complicating scenarios for sputum cytology. However, the presence of certain
patient factors in the simulated clinical scenarios (patient anxiety, poor patient-physician
relationship and multiple dynamics) influences their decision-making over-riding their
perception of guidelines.
These findings are consistent with the results of Haggerty et al2 who found that decisionmaking by some FPs, who normally followed evidence-based practice (guideline
perception) was overridden in the presence of influential patient factors. Decision-making
was influenced by patient anxiety or expectation for the cancers they studied (breast,
colon and prostate). This study of lung cancer screening decision-making demonstrated
this phenomenon for multiple patient factors (patient anxiety, expectation, positive family
history, poor patient-physician relationship).
The notion that patient factors may lead FPs to override their decision to follow
guidelines is further supported by other findings of this study. When asked in a singleitem opinion-based question if CXR is recommended for lung cancer screening, 18
participants responded that they perceived that CXR was recommended; yet, when faced
with an uncomplicated patient scenario, 23 indicated they would order a CXR. The fact
that 48% screened in the Uncomplicated Scenario contrary to prevailing national
guidelines, suggests that there must be other factors (besides the complicating factors
assessed in this study) influencing their decision-making. In summary, presence of
multiple factors (patient anxiety, expectation, positive family history of lung cancer, poor
patient-physician relationship) significantly influenced FPs decisions to screen and overrides their perception of guidelines. These findings illustrate the influence of patient
factors on evidence-based medicine for lung cancer screening decision-making.
Makers of clinical practice guidelines should consider patient context to formulate better
guidelines. Recent research promotes incorporating patient preferences and context into
the guideline development process and are easy to use for physicians.73 Patient
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preferences and context are essential to shared decision making. The level of compliance
depends on patient involvement and consideration of their specific context highlighting
the need to improve the guideline development process. Strong recommendations are
discouraged where the best decision depends on patient factors – preferences, context,
goals, values.75
The high self-reported prevalence in single item questions and measured inclination to
screen in clinical scenarios using CXR needs to be addressed. These findings on lung
cancer screening decision-making should be of considerable interest in the current culture
of health care cost reduction, for example, the Choosing Wisely Canada76 campaign
encouraging patient-physician dialog about unnecessary tests, treatments and procedures.

4.9 Implications
The study findings on FPs’ lung cancer screening decision-making suggest the following
important clinical implications:
1. Ordering of CXRs, which is against evidence-based guidelines adds unnecessary
costs and burden on the health care system.
2. Guideline discordant investigations and false positive tests cause anxiety thereby
increasing morbidity and further exposure to radiation with more investigations
and consultations without any benefit to the patient.
3. Lack of knowledge of guidelines leads to variation in practice, highlighting the
need for wide dissemination of evidence-based guidelines by CME, and/or
integration within an EMR.
4. Various strategies in guideline development such as incorporating patient
preferences, and engagement of patient values and preferences in decision-making
may be employed to implement guidelines.44,73,74,77-84
5. The need for guideline makers and those implementing quality improvement
strategies that measure adherence to guidelines to recognize that some variability
is to be expected.73,74
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4.10 Strengths
The study made use of evidence that incorporating a clinical vignettes design is a
preferred methodology to assess physician behaviour and decision-making in surveys.
Single-item questions responses are subject to recall bias and do not allow behaviour
assessment in varying patient-specific contexts which are observed in routine clinical
encounters. A clinical vignette methodology allowed simulating real life clinical
encounters and permitted studying FP’s intended behaviour in the presence of varied
patient factors. Clinical vignettes have been shown to be a valid and cost-effective
method to assess physician clinical decision-making, including those in cancer care.85-88
Peabody85 concluded that clinical case vignettes appear to be a valid and comprehensive
method to focus on actual clinical practice in an outpatient setting, rather than physician
competence. That study ranked the relative effectiveness of assessing clinical decisionmaking as 1) standardized patients, 2) clinical case vignettes and 3) chart abstraction.
Research, specifically on vignette-based surveys88 demonstrated they were more time
efficient than record reviews or using standardized patients, and more cost-effective than
standardized patients to assess clinical decision-making. Thus, the current survey that
included clinical scenarios used the best evidence-based methodology available.

4.11 Limitations
The study has the following known limitations:
1. The ability to generalize to all FPs in Saskatchewan is limited by the low response
rate. It is not possible to know if the sample was representative of the screening
behaviour of the provincial population of FPs. However, it did appear that FP
characteristics in our sample were comparable to provincial and Canadian FPs.
2. The study was limited to FPs in Saskatchewan, so the results may not reflect
behaviour of all Canadian FPs.
3. The sample size was small making it difficult to detect clinically relevant
differences. Statistical significance may not have been seen for many analyses
because the sample size was relatively small and for repeated measures, the
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Bonferroni adjustment was a strong correction to the p-value. However, there
appeared to be clinically relevant trends and additional significance might be seen
with a larger sample size. The proportions are susceptible to changes with small
variation in the allocation of participants, again due to small sample size.
4. The results are based on FPs’ reported behaviour and may be subject to
desirability bias. Further research might be done to validate self-reported data, for
example by comparison with chart audit of medical records.
5. The survey design can explore behaviour but not reasons behind the behaviour.
Future qualitative study can address this concern.

4.12 Direction for future research
The results of the present study emphasize the need to better understand reported lung
cancer screening behaviour and decision-making suggesting four potential research
studies.
1. Research to examine why FPs screen patients for lung cancer and why they order
CXR as a screening test. This research would examine the factors identified in
this study and any additional factors that influence FPs’ lung cancer screening
decision-making. This could be achieved by conducting qualitative research,
either in-depth interviews or focus groups.
2. After exploring qualitatively the factors influencing FPs' lung cancer screening, a
national Canadian survey of FPs regarding their behaviour and decision-making
for lung cancer.
3. Research to assess FPs’ actual lung cancer screening behaviour by chart audit to
address desirability bias and recall bias in self-reported behaviour in surveys.
4. Research to explore how guideline makers might engage FPs in the development
of guidelines in the context of family practice. The results may then be used to
inform guideline makers so that they can address concerns raised by their users.
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Letter of Information
Lung Cancer Screening Practices of Family Physicians in
Saskatchewan
Introduction and Purpose of Study:
You are invited to participate in a study to explore your ideas, thoughts and experiences as
a practicing family physician in Saskatchewan. The purpose of this letter is to provide you
with the information you require to make an informed decision on participating in this
research.
Who Can Participate:
You are invited to participate in this research if you are a practicing family physician in
Saskatchewan. In order to be eligible to participate you must be between the ages of 2565.
What Will the Study Involve:
Phase I of the study is a census survey to explore lung cancer screening practices.
In Phase II of the study, you may be invited to participate in an individual interview. The
interview will take place at a location and time that is convenient for you and will take
approximately thirty to forty-five minutes. The interview will be audio taped and
transcribed verbatim.
Confidentiality and Privacy:
All information for the study is confidential. Each participant is assigned an ID number.
All participant identifiers and ID numbers will remain in a master list in a passwordprotected database. The master list will remain separate from the data. The master list
linking participant names to identifiers will be held separately from the data set and
password protected or locked in a separate location (hard copy). The voice file of the
interview will be sent off-site to a professional transcriptionist to be transcribed verbatim.
If you use any names during the interview, they will be not transcribed but simply
replaced with the word "name" or "place" (e.g. John = "name"). All electronic files will be
password protected. All hardcopy forms and transcripts will be stored in a locked filing
cabinet for security.

75
Voluntary Participation:
Participation in this study is voluntary. You may refuse to participate, refuse to answer any
questions or withdraw from the study at any time.
Risks and Benefits:
We see no risks associated with this research. The benefits include gaining a better
understanding of the challenges you face regarding screening decisions for lung cancer
and to influence improvements in this aspect of practice.
Do You Have Questions:
If the results of the study are published, your name will not be used and no information
that discloses your identify will be released or published without your explicit consent to
the disclosure.
If you have any questions about your rights as a research participant or the conduct of the
study, please contact Dr. David Hill, Scientific Director, Lawson Research Institute at
(###) ###-####. Representatives of The University of Western Ontario Health Sciences
Research Ethics Board may require access to your study-related records or may follow up
with you to monitor the conduct of the research.
If you have any questions regarding your participation in this study, please contact Dr.
John Feightner, Principal Investigator at (###) ###-####
Thank you for your consideration.
Dr. John Feightner
Professor
Dr. Judith Belle Brown
Professor
Centre for Studies in Family Medicine
Department of Medicine
Schulich School of Medicine & Dentistry
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Appendix C
Analysis of Tudiver Survey Instrument
C.1 Analysis
The sample questionnaire, appended to this discussion, was provided by Dr Tudiver53 for
review. It has the following structural attributes.
1. Section I – Questions about perceptions of current cancer screening guidelines
2. Section II – Questions about which factors influence cancer screening decisions
3. Section III – Clinical vignettes (two vignettes/cancer screen, six total) to inquire
about decision to order cancer screening tests with variations in 4 patient factors
4. Section IV – Questions about respondent physician and practice characteristics
5. Section V – Questions about respondents personal experience with cancer and
cancer screening
Note that the literature53 refers to a two-part survey, where Part 1 includes Sections I, II,
IV and V and Part 2 includes Section III. A fractional factorial design ensured that each
physician received a unique questionnaire – Part 1 was common to all questionnaires but
Part 2 was unique. Part 2 of the sample questionnaire had the following notable features:
1. Two prostrate cancer screening vignettes, males only, alternated good/bad
patient/physician relationship
2. Two breast cancer screening vignettes, females only, alternated good/bad patient
physician relationship
3. Two colorectal cancer screening vignettes, female, male, alternated good/bad
patient physician relationship
4. The structure of each vignette modelled the flow of information/activity in a
clinical encounter. In addition, the style of writing employed expressed the level
of each of the four patient factors being investigated in a clinically meaningful
manner. Sequentially, patient/physician relationship factor was explained first,
then reason for the patients visit with relevance to specific cancer screening, then
medical history factor (personal, family, risk factors), then patient factors
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(expectation of screening test, significant anxiety) and then asymptomatic clinical
examination results.
Overall, Section III implemented a fractional, factorial design with six clinical scenarios,
each representing a frame (which set the context) and each having 16 variations
representing all possible combinations of the four patient factors (independent variables).
Six frames implies 6 x 16 = 96 vignettes were required in the end and many more written
during the iterative development/edit phase. The fractional factorial design required the
unique series always had one vignette with all patient factors present, one with no patient
factors present, and a random variation in patient factors in the remainder. The vignettes
were presented in random order to minimize sequence bias. It appears that the frame
position was fixed (Scenario #1-#6) so randomness must have been introduced by which
patient factor combination would appear in which frame.
The clinical case vignettes were developed and tested in 4 steps.
1. Initially authored by the clinical investigators based on their experience.
2. Submitted to 12 family physicians colleagues for empirical review of
descriptions.
3. Minimum of 9/12 (75%) had to correctly identify the intended level of each
patient factor, else modified or replaced.
Those requiring correction were submitted to another set of 12 physicians to filter again
according to 75% rule above.
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Appendix E
Detailed Methods for Questionnaire Development
E.1 Questionnaire Design Methodology
The following describes the approach taken to develop this study’s survey instrument, a
questionnaire adapted from the Tudiver et al. survey tool. The Tudiver et al. study
explored factors that influence cancer screening decision-making for prostate, breast and
colorectal cancer. Since the current study objectives were focussed specifically on lung
cancer screening, the methodology used in this study was unique.
The Tudiver et al. survey instrument was adapted to fulfil the new study objectives. Their
survey tool had questions on prostate, colorectal and breast cancer. They were replaced
with questions specifically about lung cancer screening. Questions were also added to
estimate the proportion of physicians screening by self-report and to identify which tests
were preferred.
E.2 Questionnaire Items
The questionnaire developed for this study was a derivation of the validated survey
instrument used by Tudiver et al.2,10,53 with modifications to adapt it to study how family
physicians make lung cancer screening decisions. The questionnaire is composed of 38
single item questions (some with multiple answer subparts) and six clinical case
vignettes, organized into five sections:
I. Physician perceptions of guidelines for lung cancer screening;
II. Inquiry into which medical and non-medical factors influence the participating
physician’s lung cancer screening decisions;
III. Clinical case vignettes to study the influence of factors (patient anxiety,
expectation, positive family history) on family physicians lung cancer screening
behaviour;
IV. Practice characteristics and physician demographics;
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V. Physician’s personal experiences with lung cancer and lung cancer screening
behaviour;
VI. Survey Evaluation to obtain respondent feedback on validity and reliability.
E.2.1 Section II Items to classify physicians as Screeners or NonScreeners
The survey collected data needed to classify participants into two groups – Screeners and
Non-screeners. Direct query was chosen to minimize error and introductory questions
(Section II, Q1 and Q2) were developed to examine screening behaviour. The following
discussion references the actual questionnaire attached as an appendix.
Questions 1 and 2 are identical except they address screening behaviour for two groups,
non-smokers and current or past smokers. This broadens the survey to include screening
behaviour towards non-smokers who sometimes develop lung cancer. Non-smokers are
defined as patients who have never smoked. Current or past smokers are patients who
currently smoke or have past history of smoking.
Questions 1a and 2a are ratio scale89 questions. The data they provide have a true zero
value and were treated as ratio data. We are soliciting ratio data with what appears to be
an ordinal scale with response options presented in ranges. Ranges are presented because
it’s faster for the respondent to answer the question, lowering respondent burden. Less
respondent burden will promote a higher rate of return which enhances the external
validity of the study.
Question 1b and 2b are nominal scale89 questions added to collect data on ordering
behaviour for all types of lung cancer screening tests.
Question 3-14 are ratio –scale questions. The data they provided have a true zero value
and were treated as ratio data. A 4-point Likert scale was used to ease data collection.
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E.2.2 Section III Clinical Case Vignettes
The Tudiver et al questionnaire53 made use of clinical case vignettes noting “they have
been shown to be a useful, inexpensive, and effective method for eliciting physicians’
decision-making behaviour in a simulated situation”.85 Peabody concluded that clinical
case vignettes appear to be a valid and comprehensive method to focus on actual clinical
practice in an outpatient setting, rather than physician competence.85 Their prospective
study ranked the relative effectiveness of the methods studied as:
1) Standardized patients, 2) clinical case vignettes and 3) chart abstraction. Case
vignettes have been used to examine physicians’ practice behaviour with cancer
patients.90-93
Tudiver53 stated “For research purposes, the usefulness of the clinical case vignette rests
on the ability to vary specific factors (relevant independent variables under study) from
one vignette to another, while keeping constant the surrounding factors of the case
presented (the frame).” The same rationale applies to the revised clinical case vignettes
developed for the study questionnaire.
The survey included 6 clinical case vignettes developed by one of the clinician
investigators (NJ). The vignettes vary the patient factors (independent variable) shown in
Table 1, with the dependent variable being a yes/no decision to order any of the three
screening tests (CXR, CT Chest, Sputum Cytology).
Table 1 Patient Factors Present in Clinic Vignettes
Patient Factor

Factor Present in Clinical Vignette
Scenario
#1
(Control)

Patient expects to
undergo
screening
Patient anxious
about having
lung cancer
Positive family
history of lung
cancer

Scenario
#2

Scenario
#3

Scenario
#4

Y

Scenario
#5

Scenario
#6

Y

Y

Y

Y

Y
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Patient Factor

Factor Present in Clinical Vignette
Scenario
#1
(Control)

Scenario
#2

Poor quality
physician-patient
relationship

Scenario
#3

Scenario
#4

Scenario
#5

Scenario
#6

Y

Y

E.3 Reliability and Validity
To ensure validity and to ensure appropriateness of the reading level, the survey was
piloted on three family physicians. This was followed by an interview to improve clarity
and comprehensiveness of the questionnaire. This feedback led to changes to two
questions about physician demographics: age was obtained as a range instead of an actual
age; type of practice was broadened to add Regional to existing Rural & Urban choices.
This study also contains a section to test actual physician behaviour in a simulated
clinical setting by means of a clinical experimental study component, consisting of
clinical case vignettes where testing is done in the context of a controlled environment,
one where independent variables are manipulated to examine decision-making behaviour.
The scenarios presented are intended to model real-world clinical encounters, enhancing
external validity.
References on questionnaire design and quality assessment were consulted during
questionnaire development59-68.
To increase the external validity of the study, a high rate of return was desired. This was
promoted in this study by applying best practices identified in the literature including
administration of the survey using the step-wise revised Dillman Method.58
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